No products in the cart.
Rabbit Polyclonal Anti-RANK antibody (STJ98715)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC-P, ELISA
Recommended dilution: WB 1:500-2000; IHC-P 1:50-300; ELISA 1:5000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-RANK antibody.
Check alternative names for the antibodyExpand
|CD265 antibody|CD265 antigen antibody|FEO antibody|LOH18CR1 antibody|Loss of heterozygosity, 18, chromosomal region 1 antibody|Ly109 antibody|mRANK antibody|ODFR antibody|OFE antibody|OPTB7 antibody|Osteoclast differentiation factor receptor antibody|OSTS antibody|PDB2 antibody|RANK antibody|Receptor activator of NF-KB antibody|Receptor activator of nuclear factor-kappa B antibody|RGD1563614 antibody|TNFRSF11A antibody|TRANCE R antibody|TRANCER antibody|Tumor necrosis factor receptor superfamily member 11A antibody|Tumor necrosis factor receptor superfamily, member 11a, activator of NFKB antibody|Anti-sRANKR antibody (Biotin)
SCBT cat No: sc-59981|sc-52951|sc-390655|sc-7625|sc-34249|sc-9072|sc-374360|sc-59349|sc-7624|
|Catalogue No.|| |
Human, Mouse, Rat
Anti-RANK antibody detects endogenous RANK.
Synthetic peptide from human protein at AA range: 60-120.
WB, IHC-P, ELISA
|Recommended dilution|| |
WB 1:500-2000; IHC-P 1:50-300; ELISA 1:5000-20000
|Molecular weight|| |
Anti-RANK antibody was tube-contained in PBS, pH 7.4, containing 0.02% sodium azide as Preservative and 50% Glycerol.
Anti-RANK antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
CD265 antibody, CD265 antigen antibody, FEO antibody, LOH18CR1 antibody, Loss of heterozygosity, 18, chromosomal region 1 antibody, Ly109 antibody, mRANK antibody, ODFR antibody, OFE antibody, OPTB7 antibody, Osteoclast differentiation factor receptor antibody, OSTS antibody, PDB2 antibody, RANK antibody, Receptor activator of NF-KB antibody, Receptor activator of nuclear factor-kappa B antibody, RGD1563614 antibody, TNFRSF11A antibody, TRANCE R antibody, TRANCER antibody, Tumor necrosis factor receptor superfamily member 11A antibody, Tumor necrosis factor receptor superfamily, member 11a, activator of NFKB antibody
|Database links|| |
|Protein function|| |
Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. .
|Protein tissue specificity|| |
Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland.
|Involvement in disease|| |
Familial expansile osteolysis (FEO) [MIM:174810]: Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Paget disease of bone 2, early-onset (PDB2) [MIM:602080]: A form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Osteopetrosis, autosomal recessive 7 (OPTB7) [MIM:612301]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. . Note=The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Contains 4 TNFR-Cys repeats.
|Protein cellular localization|| |
Isoform 1: Cell membrane ; Single-pass type I membrane protein .; Isoform RANK-e5a: Cell membrane ; Single-pass type I membrane protein .
|Research area|| |
<a href="http://antibodyplus.com/research-areas/">All research areas</a>><a href="http://antibodyplus.com/Lymphocyte-Signaling/">Lymphocyte Signaling</a>><a href="http://antibodyplus.com/product-tag/RANK/">RANK</a><br><a href="http://antibodyplus.com/product-tag/Lymphocyte-Signaling/"> (View all antibody categories related to Lymphocyte Signaling)</a>
AntibodyPlus can customize Anti-RANK antibody according to your requirement, including bulk product size,etc. Please contact <a href="mailto:firstname.lastname@example.org">email@example.com</a>. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: